Erzotabart Biosimilar - Research Grade

Human

CD38

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human CD38 (OKT10) Antibody (ICH1157), Daratumumab Biosimilar - Research Grade (ICH4020), Isatuximab Biosimilar - Research Grade (ICH5028), Felzartamab Biosimilar - Research Grade (ICH5547), Lumrotatug Biosimilar - Research Grade (ICH5661), Mezagitamab Biosimilar - Research Grade (ICH5679)

https://www.imgt.org/mAb-DB/

ICH3002

P28907

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of erzotabart, an investigational anti-CD38 human IgG1 kappa antibody, supplied strictly for research use. It reproduces the target specificity of the originator molecule (binding the CD38 ectoenzyme) so investigators can study CD38 engagement, blockade, and Fc-mediated effector biology without sourcing scarce clinical material. Because it is manufactured as a research reagent rather than a drug, it is well suited to controlled in-vitro and preclinical workflows: flow cytometry and binding characterization, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP) assays, epitope and competition studies, isotype-matched positive controls, and as a benchmarking or reference standard against other anti-CD38 candidates. It is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, screening campaigns, and scale-dependent preclinical models. It is not the clinical drug and is not intended for human or veterinary use. Guidance provided for ichorbio to review. CD38 (UniProt P28907) is a type II transmembrane glycoprotein that acts as a multifunctional ectoenzyme and cell-surface receptor. Enzymatically it is an ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase, and it also degrades NAD+, thereby regulating intracellular calcium signaling and NAD+ homeostasis. CD38 is expressed on many hematopoietic cells and is upregulated on activated lymphocytes, and it is notably high on plasma cells and malignant plasma cells, which is why it is a well-established target in multiple myeloma. Beyond enzymatic activity, CD38 participates in adhesion and signaling through interactions with partners such as CD31. Its restricted-yet-elevated expression on antibody-secreting and tumor cells makes it attractive for antibody-mediated effector mechanisms including CDC, ADCC, and ADCP.

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, ADPRC 1, cADPr hydrolase 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Erzotabart biosimilar available in bulk or gram quantities?

A: Yes — the Erzotabart biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Erzotabart suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Erzotabart biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Erzotabart that binds CD38.